• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Yaupon Therapeutics, Inc. - Product Pipeline Review - Q4 2010 - Product Image

Yaupon Therapeutics, Inc. - Product Pipeline Review - Q4 2010

  • ID: 1447111
  • November 2010
  • 33 pages
  • Global Markets Direct

Yaupon Therapeutics, Inc. – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Yaupon Therapeutics, Inc. - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Yaupon Therapeutics, Inc. - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Yaupon Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Yaupon Therapeutics, Inc. Snapshot
Yaupon Therapeutics, Inc. Overview
Key Information
Key Facts
Yaupon Therapeutics, Inc. – Research and Development Overview
Key Therapeutic Areas
Yaupon Therapeutics, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Yaupon Therapeutics, Inc. – Pipeline Products Glance
Yaupon Therapeutics, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Yaupon Therapeutics, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Yaupon Therapeutics, Inc. – Drug Profiles
Clearazide
Product Description
Mechanism of Action
R&D Progress
Lobeline
Product Description
Mechanism of Action
R&D Progress
Nitrogen Mustard
Product Description
Mechanism of Action
R&D Progress
Drug for skin inflammation
Product Description
Mechanism of Action
R&D Progress
YT-1006
Product Description
Mechanism of Action
R&D Progress
Yaupon Therapeutics, Inc. – Pipeline Analysis
Yaupon Therapeutics, Inc. – Pipeline Products by Therapeutic Class
Yaupon Therapeutics, Inc. Pipeline Products By Target
Yaupon Therapeutics, Inc. – Pipeline Products by Route of Administration
Yaupon Therapeutics, Inc. – Pipeline Products by Molecule Type
Yaupon Therapeutics, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Sep 24, 2010: Yaupon Announces Positive Results From Pivotal Study Of Mechlorethamine Gel In Early-Stage Cutaneous T-cell Lymphoma
Sep 24, 2010: Yaupon Announces Positive Results From Pivotal Study Of Mechlorethamine Gel In Early-Stage Cutaneous T-cell Lymphoma
Jun 29, 2009: Yaupon Therapeutics Completes Patient Enrollment For Pivotal Phase 2 Study Of Clearazide For Treatment Of Cutaneous T-cell Lymphoma
Oct 26, 2004: Yaupon Therapeutics Inc. Initiates Clinical Trials For First Agent To Treat Epidemic Of Methamphetamine Addiction
Financial Deals Landscape
Yaupon Therapeutics, Inc., Deals Summary, 2004 to 2010
Yaupon Therapeutics, Inc. Detailed Deal Summary
Venture Financing
Yaupon Therapeutics Secures $14.5 Million In Series C Financing
Yaupon Therapeutics Secures $4 Million In Series B Financing
Yaupon Therapeutics Secures $0.5 Million In Seed Round Of Financing
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS